Bioactive lipids derived from arachidonic acid metabolism in different types of renal replacement therapy. (August 2017)

• Record Type: Journal Article
• Authors: Stępniewska, Joanna; Dołęgowska, Barbara; Puchałowicz, Kamila; Gołembiewska, Edyta; Ciechanowski, Kazimierz
• Is Part Of: Chemistry and physics of lipids. Volume 206(2017)
• Page Start: 71
• Page End: 77
• Publication Date: 2017-08
• Subjects: Arachidonic acid -- Active eicosanoids -- Oxidative stress -- Chronic kidney disease -- Platelets -- Haemodialysis -- Peritoneal dialysis; Lipids -- Periodicals; Lipids -- Periodicals; Lipides -- Périodiques; Lipids; Periodicals; Electronic journals; 547.77
• DOI: 10.1016/j.chemphyslip.2017.05.003
• Languages: English
• ISSNs: 0009-3084

Abstract

Highlights: The impaired metabolism of AA in CKD causes further deterioration of kidney function and cardiovascular complications. The type of renal replacement therapy and oxidative stress influence on concentrations of AA derivatives. Haemodialysis treatment led to the significant decrease in TXB2 plasma concentration. 20-HETE concentrations were significantly higher in HD patients, than in PD and CKD 3–5 groups. Active AA metabolites might be considered as novel biomarkers of kidney injury. Abstract: Introduction: Metabolism and plasma concentration of lipids and lipid-derived compounds play an important role in kidney physiology and pathological processes. The component of membrane phospholipids − arachidonic acid (AA) and its active derivatives − eicosanoids are involved in the development of hypertension, diabetes, inflammation and may contribute to progression of chronic kidney disease (CKD). The purpose of the study was to determine, whether the type of renal replacement therapy has an effect on eicosanoids metabolism. Materials and methods: The study included 145 patients with CKD: on conservative treatment (n = 68), on peritoneal dialysis (PD) (n = 23) and undergoing chronic haemodialysis (HD) (n = 54). The concentrations of TXB2, 20-HETE, 8-epi-PGF2α in platelet poor plasma (PPP) were determined using the ELISA method and 5-HETE, 12-HETE, 15-HETE were measured using the RP-HPLC. Results: The concentrations of TXB2 in HD group, both before (2.28 ± 0.72 ng/mL) and after (1.49 ± 0.63 ng/mL) haemodialysis treatment differed significantly from PD group (57.76 ± 6.13 ng/mL). Haemodialysis session led to the significant decrease in TXB2 plasma concentration (p = 0.046). 20-HETE concentrations in HD group (113.55 ± 107.54 pg/mL and 199.54 ± 142.98 pg/mL before and after haemodialysis, respectively) were significantly higher than in CKD 3–5 group (8.96 ± 12.66 pg/mL) and PD group (47.78 ± 34.07 pg/mL). The highest concentration of 12-HETE was obtained in PD patients (3.58 ± 3.99 ng/mL) and differed significantly from HD group after haemodialysis (0.97 ± 0.28 ng/mL) and CKD3-5 group (1.06 ± 0.52 ng/mL). The concentrations of 5-HETE, 15-HETE and 8-epi-PGF2α -III did not differ significantly among examined groups. Conclusions: The concentrations of active AA metabolites depend on the mode of renal replacement therapy and are associated with intensity of oxidative stress. They might be considered as potential indicators of kidney damage.